Merck KGaA

MRK

DE0006599905

Pharmaceuticals

Real-time Estimate Tradegate Other stock markets 03:12:12 2024-05-15 am EDT			5-day change	1st Jan Change
164.4 ^EUR	+3.82%		+3.13%	+9.85%

07:31am	Merck KGaA Posts Lower Q1 Attributable Profit, Net Sales	MT
07:30am	Merck KGaA's Q1 adjusted profit declines less than feared	RE

MERCK KGAA : Warburg Research sticks Neutral

May 12, 2021 at 05:36 am EDT

Warburg Research analyst Ulrich Huwald maintains his Neutral opinion on the stock. The target price has been raised to EUR 123 from EUR 118.

Latest news about Merck KGaA

Merck KGaA Posts Lower Q1 Attributable Profit, Net Sales	01:31am	MT
Merck KGaA's Q1 adjusted profit declines less than feared	01:30am	RE
Merck KGaA Confirms Outlook After Drop in Sales, Earnings	01:30am	DJ
Cinven to explore $3 billion sale of software maker Jaggaer, sources say	May. 13	RE
MERCK KGAA : UBS reiterates its Buy rating	May. 08	ZD
MERCK KGAA : Gets a Buy rating from JP Morgan	May. 07	ZD
MERCK KGAA : Receives a Buy rating from Deutsche Bank	May. 07	ZD
Biocartis, Merck KGaA Expand Cancer Biomarker Testing Collaboration into MENA Region	May. 06	MT
MERCK KGAA : Gets a Buy rating from UBS	May. 06	ZD
Biocartis Announces Expansion of Its Collaboration with Merck Serono Middle East and North Africa	May. 06	CI
MERCK KGAA : JP Morgan maintains a Buy rating	May. 03	ZD
MERCK KGAA : Jefferies keeps its Buy rating	May. 01	ZD
Habeck's 'pharma trip' - industry sees structural problems	Apr. 29	DP
Former SAP Executive Board member Kleinemeier to permanently head Merck's Supervisory Board	Apr. 26	DP
Transcript : Merck KGaA - Shareholder/Analyst Call	Apr. 26
Scholz pledges further support for the pharmaceutical industry	Apr. 25	DP
Scholz promises support for pharma sector in Germany as Merck invests	Apr. 25	RE
Merck KGaA Starts Building EUR300 Million Life Science Research Center in Germany	Apr. 25	MT
Scholz visits Merck and Family Business Days	Apr. 24	DP
US competitor Danaher boosts Merck KGaA and Sartorius	Apr. 23	DP
MERCK KGAA : Barclays reiterates its Buy rating	Apr. 19	ZD
Study: US companies outpace Europe and Asia in research spending	Apr. 18	DP
Agronomics Portfolio Company Mosa Meat Raises EUR40 Million to Beef Up Production	Apr. 17	MT
Merck KGaA Rolls Out New Genetic Stability Assay Platform	Apr. 16	MT
MERCK : A peer group tidy up	Apr. 13

Merck KGaA is one of the world's leading pharmaceutical and chemical groups. Net sales break down by family of products as follows: - solutions and products for scientific and biotechnological research (44.2%); - pharmaceutical products (38.4%): prescription drugs for the treatment of diabetes, cancer, multiple sclerosis, infertility, cardiovascular disease, central nervous system disorders, inflammatory disorders, etc.; - performance materials for the electronics industry (17.4%): semiconductor materials, liquid crystals, pigments and additives, carbon-based organic materials, etc. Net sales are distributed geographically as follows: Germany (4.8%), Europe (24%), China (12.9%), Asia/Pacific (20.1%), the United States (26.8%), North America (1.6%), Latin America (6.3%), Middle East and Africa (3.5%).

Sector

Pharmaceuticals

Calendar

01:00am - Q1 2024 Earnings Release

Related indices

STOXX EUROPE 600 (EUR) , DAX

More about the company

Income Statement Evolution

More financial data

Analysis / Opinion

MERCK : A peer group tidy up

April 13, 2024 at 04:06 pm EDT

Merck KGaA : A European big pharma with positive momentum

January 20, 2023 at 05:51 am EST

More Strategies

Ratings for Merck KGaA

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

158.3 EUR

Average target price

179.8 EUR

Spread / Average Target

+13.59%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Specialty & Advanced Pharmaceuticals

	1st Jan change	Capi.
MERCK KGAA	+9.85%	74.45B
KYOWA KIRIN CO. LTD.	+11.35%	9.18B
SK BIOPHARMACEUTICALS CO., LTD.	-12.85%	5.02B
SHENYANG XINGQI PHARMACEUTICAL CO.,LTD.	+60.16%	5.03B
YUHAN CORPORATION	+1.60%	3.82B
BETTA PHARMACEUTICALS CO., LTD.	-19.20%	2.41B
INDIVIOR PLC	+18.65%	2.39B
SHANGHAI SHYNDEC PHARMACEUTICAL CO., LTD.	+24.62%	2.26B
CHANGCHUN BCHT BIOTECHNOLOGY CO.	-27.46%	2.27B
VELOXIS PHARMACEUTICALS A/S	-0.50%	1.64B

Specialty & Advanced Pharmaceuticals

Merck KGaA

Equities

MRK

DE0006599905

Pharmaceuticals

MERCK KGAA : Warburg Research sticks Neutral

Latest news about Merck KGaA

Chart Merck KGaA

Company Profile

Income Statement Evolution

Analysis / Opinion

Ratings for Merck KGaA

Analysts' Consensus

EPS Revisions

Quarterly earnings - Rate of surprise

Sector Specialty & Advanced Pharmaceuticals